Latest news with #NasdaqCapitalMarket
Time of India
3 days ago
- Business
- Time of India
Unbelievable! Stock of herbal medicine company, with zero revenue, rallies whopping 46,000% - what's causing this surprising rise?
The Hong Kong-based organisation, which began trading on the Nasdaq Capital Market in 2021, has witnessed an inexplicable 460-fold increase in 2025. (AI image) Imagine a stock rising a whopping 46,000%, when the company makes no revenue! As unbelievable as it sounds, that's the case for a herbal medicine biotech company. The shares of Regencell Bioscience Holdings Limited have jumped by a mind-boggling 46,000% in 2025, despite having no revenue generation since its establishment! The Hong Kong-based organisation, which began trading on the Nasdaq Capital Market in 2021, has witnessed an inexplicable 460-fold increase in 2025, despite minimal corporate announcements. According to its latest annual SEC filing, the company remains in its research and development phase, having generated no revenue since its inception. According to a Bloomberg report, Regencell Bioscience Holdings Limited has transformed from a penny stock in April to achieve a market value of approximately $30 billion. The company's market capitalisation stood at merely $53 million a year ago. The firm reported a net loss of $4.4 million for the fiscal year ending June 2024, which is a 28% reduction compared to the previous period. The company's board sanctioned a 38-for-1 stock split in early 2025. Following the split's implementation on Monday, the share price rose by 283%, marking its highest single-day increase in nearly a year and triggering multiple trading halts due to volatility. About Regencell Bioscience Holdings: The Stock That Rose 46,000% The company has primarily sustained its operations through shareholder loans and IPO proceeds, as per the SEC documentation. The IPO generated gross proceeds of $21.85 million, whilst additional net proceeds of $2.85 million were obtained from over allotment shares and the exercise of 325,000 shares. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo Based in the Cayman Islands, the organisation specialises in developing natural herb-based medicines for treating neurological conditions such as ADHD and autism spectrum disorder, according to its website. Their product candidates are derived from traditional Chinese medicine (TCM) formulations, which they emphasise contain exclusively natural components without synthetic additives. "We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," the company stated in an October filing. In 2022, the organisation expanded into Covid-19 treatments, conducting clinical trials for their experimental comprehensive treatment approach. Regencell reported that their 2022 trial data demonstrated the treatment's effectiveness in alleviating and eliminating Covid symptoms within six days, though these findings await peer review validation. The significant fluctuations in Regencell shares can be attributed to its limited float, the Bloomberg report said. Of the company's approximately 500 million outstanding shares, merely 30 million are tradeable, representing about 6% of total shares. This stands in stark contrast to Apple Inc., with 98% tradeable shares, and Tesla Inc., with 87%. The remaining Regencell shares are held by insiders, with Chief Executive Officer Yat-Gai Au controlling 86%, according to Bloomberg's compiled holding data. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Straits Times
4 days ago
- Business
- Straits Times
Nasdaq-listed herbal medicine stock with no sales rallies 64,000%
The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than US$20 billion (S$25.6 billion) in market value. PHOTO: ST FILE NEW YORK - A Nasdaq-listed stock focused on herbal medicine has spiked by more than 64,000 per cent so far in 2025 and yet, the company itself has made zero revenue – much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than US$20 billion (S$25.6 billion) in market value. A year ago, the stock had a market capitalisation of just US$53 million. This is despite the company having a net loss of US$4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Earlier in June the company said its board approved a 38-for-1 stock split. When the split took effect on June 16, shares soared as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 640-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission (SEC). A representative for Regencell didn't immediately respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders like ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components.' 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering, the SEC filing showed. It said its gross proceeds from its IPO were US$21.85 million, with additional net proceeds of US$2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6 per cent of shares, compared to Apple – which has about 98 per cent available – and Tesla's 87 per cent. Insiders own the remaining Regencell shares, with chief executive officer Yat-Gai Au's ownership accounting for 86 per cent, according to holding data compiled by Bloomberg. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
4 days ago
- Business
- Business Times
Herbal medicine stock with no sales rallies 64,000%
[NEW YORK] A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year and yet, the company itself has made zero revenue – much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth more than US$20 billion in market value. A year ago, the stock had a market capitalisation of just US$53 million. This is despite the company having a net loss of US$4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Earlier this month the company said its board approved a 38-for-1 stock split. When the split took effect on Monday (Jun 16), shares rose as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 640-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission (SEC). A representative for Regencell did not immediately respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders such as ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components'. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid-19 symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering (IPO), the SEC filing showed. It said its gross proceeds from its IPO were US$21.85 million, with additional net proceeds of US$2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6 per cent of shares, compared to Apple – which has about 98 per cent available – and Tesla's 87 per cent. Insiders own the remaining Regencell shares, with chief executive officer Yat-Gai Au's ownership accounting for 86 per cent, according to holding data compiled by Bloomberg. BLOOMBERG
Yahoo
4 days ago
- Business
- Yahoo
Herbal Medicine Stock With No Sales Rallies 64,000%
(Bloomberg) — A biotech stock focused on herbal medicine has surged by more than 46,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space As American Architects Gather in Boston, Retrofits Are All the Rage The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth nearly $30 billion in market value. A year ago, the stock had a market capitalization of just $53 million. This is despite the company having a net loss of $4.4 million for its fiscal year that ended June 2024, a 28% decrease from the previous year. Earlier this month the company said its board approved a 38-for-1 stock split. When the split took effect Monday, shares rose 283% — their biggest one-day jump in nearly a year on a closing basis — to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 460-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission. A representative for Regencell didn't respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders like ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components.' 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering, the SEC filing showed. It said its gross proceeds from its IPO were $21.85 million, with additional net proceeds of $2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6% of shares, compared to Apple Inc. — which has about 98% available — and Tesla Inc.'s 87%. Insiders own the remaining Regencell shares, with Chief Executive Officer Yat-Gai Au's ownership accounting for 86%, according to holding data compiled by Bloomberg. (Updates with closing prices throughout.) American Mid: Hampton Inn's Good-Enough Formula for World Domination The Spying Scandal Rocking the World of HR Software How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants US Allies and Adversaries Are Dodging Trump's Tariff Threats As Companies Abandon Climate Pledges, Is There a Silver Lining? ©2025 Bloomberg L.P. Inicia sesión para acceder a tu cartera de valores
Yahoo
4 days ago
- Business
- Yahoo
Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares
ATHENS, Greece, June 16, 2025 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the 'Company'), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, today announced a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (the 'Series A Preferred Shares'), payable on June 30, 2025 to holders of record as of June 25, 2025. The dividend payment relates to the period from the last dividend payment date for the Series A Preferred Shares on March 30, 2025, through June 29, 2025. There are 795,878 Series A Preferred Shares outstanding as of the date hereof. The Series A Preferred Shares trade on the Nasdaq Capital Market under the ticker symbol 'IMPPP.' ABOUT IMPERIAL PETROLEUM INC. IMPERIAL PETROLEUM INC. is a ship-owning company providing petroleum products, crude oil and drybulk seaborne transportation services. The Company owns a total of seventeen vessels on the water - seven M.R. product tankers, two suezmax tankers, three handysize drybulk carriers, three supramax drybulk carriers and two kamsarmax drybulk vessels - with a total capacity of 1,082,800 deadweight tons (dwt), and has contracted to acquire an additional two supramax drybulk carriers of 111,200 dwt aggregate capacity. Following these deliveries, the Company's fleet will count a total of 19 vessels with an aggregate capacity of 1.2 million dwt. IMPERIAL PETROLEUM INC.'s shares of common stock and 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock are listed on the Nasdaq Capital Market and trade under the symbols 'IMPP' and 'IMPPP,' respectively. Forward-Looking Statements Matters discussed in this release may constitute forward-looking statements. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although IMPERIAL PETROLEUM INC. believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, IMPERIAL PETROLEUM INC. cannot assure you that it will achieve or accomplish these expectations, beliefs or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, geopolitical conditions, including any trade disruptions resulting from tariffs and other protectionist measures imposed by the United States or other countries, general market conditions, including changes in charter hire rates and vessel values, charter counterparty performance, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled drydockings, changes in IMPERIAL PETROLEUM INC's operating expenses, including bunker prices, drydocking and insurance costs, ability to obtain financing and comply with covenants in our financing arrangements, actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, the conflict in Ukraine and related sanctions, the conflicts in the Middle East, potential disruption of shipping routes due to ongoing attacks by Houthis in the Red Sea and Gulf of Aden or accidents and political events or acts by terrorists. Risks and uncertainties are further described in reports filed by IMPERIAL PETROLEUM INC. with the U.S. Securities and Exchange Commission. Company Contact: Fenia Sakellaris IMPERIAL PETROLEUM INC. E-mail: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
